Pharma News

This section covers the managerial aspects in the Pharma industry.

Eurofins Scientific to Acquire Villapharma in Spain

Friday, December 30, 2016

Eurofins Scientific a world leader in providing analytical support to the global pharmaceutical industry announces the signing of an agreement to acquire Villapharma Research SL Villapharma in Spain The transaction is expected to close in February 2017 upon fulfilment of customary closing conditions..

U.S. FDA rejects Cempra's antibiotic for pneumonia

Friday, December 30, 2016

Cempra Inc said the US Food and Drug Administration rejected its antibiotic for communityacquired bacterial pneumonia CABP citing inadequate data on the drug39s impact on the liver and unresolved manufacturing issues An independent panel to the US FDA in November narrowly voted in favor of the drug..

Mylan Launches Generic Zovia® Tablets

Thursday, December 29, 2016

Mylan NV announced the US launch of Ethynodiol Diacetate and Ethinyl Estradiol Tablets USP 1 mg 005 mg Mylan39s product was determined to be bioequivalent and therefore therapeutically equivalent to the reference listed drug Zovia 150E28 Tablets Watson Mylan39s subsidiary Jai Pharma Limited receive..

Versartis enters commercial supply agreement with Boehringer Ingelheim Biopharmaceuticals

Thursday, December 29, 2016

Versartis Initial term of agreement continues for period of 8 years after initial term agreement will automatically renew for periods of 3 years each Says on Dec 21 co entered into a commercial supply agreement with Boehringer Ingelheim Biopharmaceuticals GMBH Versartis Inc says pursuant to agree..

Shire Announces FDA Approval of Adynovate® for use in Children and Surgical Settings

Wednesday, December 28, 2016

Shire plc announced that the US Food and Drug Administration FDA has approved ADYNOVATE Antihemophilic Factor Recombinant PEGylated an extended circulating halflife recombinant Factor VIII rFVIII treatment for hemophilia A in pediatric patients under 12 years of age The FDA also approved ADYNOVATE f..

Apricus Biosciences Announces the Launch of Vitaros® for the Treatment of Erectile Dysfunction

Wednesday, December 28, 2016

Apricus Biosciences Inc a biopharmaceutical company advancing innovative medicines in urology and rheumatology today announced the launch of Vitaros Apricus novel ondemand topical cream for the treatment of erectile dysfunction ED in Lebanon by Elis Pharmaceuticals Ltd Elis Richard Pascoe Chief Exe..

Lupin gets USFDA nod for hypertension treatment drug in US

Tuesday, December 27, 2016

Drug major Lupin has received tentative approval from the US health regulator to sell Olmesartan medoximil tablets used for treating high blood pressure in the American market It has received tentative rpt tentative approval for Olmesartan medoximil tablets 5 mg 20 mg and 40 mg from the US Food and..

Kubota Pharmaceutical Holdings Signs Letter of Intent to Form a Joint Venture with SBI Holdings

Monday, December 26, 2016

Kubota Pharmaceutical Holdings Co Ltd a clinicalstage ophthalmology company committed to translating innovation into a diverse portfolio of drugs and devices to preserve and restore vision for millions of people worldwide and SBI Holdings Inc SBI a financial services and asset management company bas..

KYORIN Holdings to transfer unit to Taisho Pharmaceutical

Monday, December 26, 2016

KYORIN Holdings Inc Says it to transfer its Japanbased unit DrProgram to Taisho Pharmaceutical Co Ltd that is a unit of Taisho Pharmaceutical Holdings Co Ltd Transaction price is not disclosed Says the transaction planned effective on April 1 2017 ..

Pfizer Completes Acquisition of Small Molecule Anti-Infective Business From AstraZeneca

Saturday, December 24, 2016

Pfizer Inc announced that it has completed the acquisition of the development and commercialization rights to AstraZenecas latestage small molecule antiinfective business primarily outside the United States The agreement includes the commercialization and development rights to the newly approved EU ..

Taro Announces Sale of U.S. Rights to Keveyis® to Strongbridge Biopharma plc

Saturday, December 24, 2016

Taro Pharmaceutical Industries Ltd announced the sale of US rights to Keveyis dichlorphenamide to Strongbridge Biopharma plc Strongbridge a global commercialstage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet need Kev..

Dipexium Pharmaceuticals and PLx Pharma Announce Merger Agreement

Friday, December 23, 2016

Dipexium Pharmaceuticals Inc and PLx Pharma Inc a privately held latestage specialty pharmaceutical company announced today that they have entered into a definitive agreement under which PLx Pharma will merge with a whollyowned subsidiary of Dipexium in an allstock transaction Following closing Dipe..

Roche’s emicizumab for haemophilia A meets primary endpoint in phase III study

Friday, December 23, 2016

Roche announced that the primary endpoint has been met for the phase III HAVEN 1 study evaluating emicizumab prophylaxis in people 12 years of age or older with haemophilia A and inhibitors to factor VIII The study showed a statistically significant reduction in the number of bleeds over time in peo..

PharmaMar and Chugai Pharmaceutical Enter into a License and Commercialization Agreement

Friday, December 23, 2016

PharmaMar has announced today the signing of an exclusive license development and commercialization agreement with Chugai Pharmaceutical Co Ltd TSE 4519 for its third marinederived anticancer drug PM1183 lurbinectedin in Japan Under the terms of this agreement PharmaMar will receive an upfront payme..

Incyte and Merus Entered into Research Collaboration to Discover and Develop Bispecific Antibodies

Thursday, December 22, 2016

Incyte Corporation and Merus NV announced that they have entered into a global strategic collaboration agreement focused on the research discovery and development of bispecific antibodies utilizing Merus proprietary Biclonics technology platform The Collaboration and License Agreement grants Incyte ..

Concert Pharmaceuticals Initiates Phase 2 Clinical Trial Evaluating CTP-656

Thursday, December 22, 2016

Concert Pharmaceuticals Inc announced the initiation of a USbased Phase 2 clinical trial evaluating CTP656 deuterated ivacaftor a next generation CFTR potentiator being developed for the treatment of cystic fibrosis CTP656 was created based on Concerts application of deuterium chemistry to modify iv..

Novartis out-licenses three COPD products in the US

Thursday, December 22, 2016

Novartis announced that it has signed a licensing agreement with Sunovion Pharmaceuticals Inc Sunovion for the US commercial rights to its three treatments for chronic obstructive pulmonary disease COPD Utibron Neohaler indacaterolglycopyrrolate inhalation powder Seebri Neohaler glycopyrrolate inhal..

Allergan to Acquire Acelity L.P. Inc.'s LifeCell Corporation for $2.9 Billion

Wednesday, December 21, 2016

Allergan plc a leading global biopharmaceutical company and Acelity today announced that they have entered into a definitive agreement under which Allergan has agreed to acquire the regenerative medicine company LifeCell for 29 billion in cash subject to customary adjustments The acquisition combin..

Soligenix Advances Collaboration with IDT Biologika

Wednesday, December 21, 2016

Soligenix Inc a latestage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need announced today that it has extended its collaboration with IDT Biologika hereafter referred to as IDT for the manufacture of RiVax the C..

X-Chem Entered into Multi-Target Drug Discovery Collaboration with Taiho Pharmaceutical

Wednesday, December 21, 2016

XChem Inc a privately held biotechnology company focused on applying its innovative drug discovery capabilities to the generation of novel small molecule therapeutics today announced that it entered into a multitarget drug discovery collaboration with Taiho Pharmaceutical Co Ltd This collaboration w..

TOP